top of page
targeting resistance-causing molecular mechanisms
there is an unmet need for durable therapeutic treatments for cancer patients, as current drugs often lose their effectiveness over time. drug resistance therefore remains a major limiting factor to patient survival. basel-based tolremo is developing a new wave of novel resistance-breaking therapies by targeting the resistance-causing molecular mechanisms right from the start.
treating patients with the right drug at the right time
by combining tolremo’s add-on compounds with existing cancer drugs and a proprietary screening platform, the company aims to ensure that the right patient is treated with the right drug at the right time.
bottom of page